Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 i
Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC).
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.
Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.
FDA approves Novocure’s Optune Lua
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
NovoCure’s Optune Lua, a wearable indicated for patients with metastatic non-small cell lung cancer has received approval from the US FDA.
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung cancer.
Novocure shares soar 33% as FDA approves lung cancer treatment
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment
Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung cancer cells. This innovative technology is based on the use with low intensity and with continuity of electric fields that operate with different frequencies and it has been presented in some clinical trials.
The American Journal of Managed Care
3d
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
3d
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Reaches tentative union deal
Philip Zimbardo dies at 91
Netanyahu's home targeted
Frozen waffles recalled
OK classroom Bible suit
PG&E shuts off power
Three Americans detained
2024 induction ceremony
NC breaks turnout record
Fire prompts evacuations
Emergency abortion ruling
Calif. oil refinery closure
Judge unseals new evidence
Bladder cancer drug pulled
Antitrust ruling delayed
At decade-high level
School shooting report
La Nina could arrive soon
Republicans appeal ruling
Ex-MN congressman dies
Nationwide blackout in Cuba
NK sending troops to RU?
G7 ministers back Ukraine
Opioid suits settlement deal
To furlough 700 workers
US deficit reaches $1.8T
$4M LAPD fentanyl seizure
Challenges military listing
Feedback